Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
AlloVir (ALVR)
NASDAQ:ALVR
AlloVir (ALVR) Stock Price & Analysis
339 Followers
ALVR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.58 - $3.75
Previous Close$0.74
Volume320.73K
Average Volume (3M)395.41K
Market Cap
$84.26M
Enterprise Value-$38.01M
Total Cash (Recent Filing)$140.53M
Total Debt (Recent Filing)$18.34M
Price to Earnings (P/E)―
Beta1.52
Next Earnings
Aug 01, 2024EPS Estimate
-$0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.66
Shares Outstanding115,003,325
10 Day Avg. Volume304,681
30 Day Avg. Volume395,410
Standard Deviation0.24
R-Squared0.03
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)0.59
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.24
Forecast
1Y Price Target
$1.00Price Target Upside34.16% Upside
Rating ConsensusHold
Number of Analyst Covering1
AlloVir News
PremiumCompany Announcements
AlloVir Finalizes $7 Million Lease Termination Deal
PremiumCompany Announcements
AlloVir Ends Lease Agreement with AMAG Pharmaceuticals
PremiumCompany Announcements
AlloVir Approves Executive Bonuses for Potential 2024 Buyout
PremiumCompany Announcements
AlloVir Faces Delisting Risk, Considers Reverse Split to Comply
Bulls Say, Bears Say
Bulls Say
Financial PerformanceSG&A expenses were below analyst and consensus estimates, suggesting effective cost management.
Research And DevelopmentFor 4Q23, R&D spending was above expectations, indicating investment in future growth.
Strategic DirectionUpcoming catalysts include the outcome of the review of strategic alternatives, which could impact the company’s future direction.
Bears Say
R&D ExpensesR&D expenses were significantly higher than estimates, which could indicate increased costs.
SG&A ExpensesSG&A expenses were also above estimates, suggesting unexpected operational costs.
Strategic ReviewALVR reported 1Q24 results but provided no updates on the timetable for the strategic review process.
---
Ownership Overview
Currently, No data available
---
ALVR FAQ
What was AlloVir’s price range in the past 12 months?
AlloVir lowest stock price was $0.58 and its highest was $3.75 in the past 12 months.
What is AlloVir’s market cap?
Currently, no data Available
When is AlloVir’s upcoming earnings report date?
AlloVir’s upcoming earnings report date is Aug 01, 2024 which is in 9 days.
How were AlloVir’s earnings last quarter?
AlloVir released its earnings results on May 02, 2024. The company reported -$0.26 earnings per share for the quarter, missing the consensus estimate of -$0.157 by -$0.103.
Is AlloVir overvalued?
According to Wall Street analysts AlloVir’s price is currently Undervalued.
Does AlloVir pay dividends?
AlloVir does not currently pay dividends.
What is AlloVir’s EPS estimate?
AlloVir’s EPS estimate is -$0.1.
How many shares outstanding does AlloVir have?
AlloVir has 115,003,330 shares outstanding.
What happened to AlloVir’s price movement after its last earnings report?
AlloVir reported an EPS of -$0.26 in its last earnings report, missing expectations of -$0.157. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of AlloVir?
Among the largest hedge funds holding AlloVir’s share is Graham Capital Management, L.P.. It holds AlloVir’s shares valued at N/A.
---
AlloVir Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$1.00 (34.16% Upside)
$1.00 (34.16% Upside)
Blogger Sentiment
Bullish
ALVR Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 2.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $37.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 1.6%
Last 30 Days ▼ 1.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-78.11%
12-Months-Change
Fundamentals
Return on Equity
-114.36%
Trailing 12-Months
Asset Growth
-40.94%
Trailing 12-Months
Company Description
AlloVir
AlloVir Inc is a late clinical-stage cell therapy company. It is developing allogeneic T cell therapies to treat and prevent devastating viral diseases. The firm's pipeline includes ALVR106, ALVR109, ALVR108, and others. The company's product candidate, Viralym-M, is a multi-VST therapy targeting five viruses namely BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6.
---
ALVR Stock 12 Month Forecast
Average Price Target
$1.00
▲(34.16% Upside)
Technical Analysis
Best Analysts Covering ALVR
1 Year
1 Year Success Rate
2/11 ratings generated profit
1 Year Average Return
-51.05%
downgraded a sell rating 7 months ago
Copying Anupam Rama's trades and holding each position for 1 Year would result in 18.18% of your transactions generating a profit, with an average return of -51.05% per trade.
---